Skip to main content
Premium Trial:

Request an Annual Quote

Freenome Partners With Geisinger to Recruit Patients for Multi-Cancer Screening Study

NEW YORK – Freenome said Wednesday that Pennsylvania health system Geisinger has joined on as a study partner for the company's ongoing Sanderson Study, a prospective effort employing and assessing Freenome's multi-cancer screening technology in certain high- or elevated-risk populations.

Freenome's test combines tumor and non-tumor signals with machine learning to detect cancer in its earliest stages from a standard blood draw. In the Sanderson study, the company is collecting both traditional and real-world data to generate evidence of clinical validity and to continually refine the assay's performance. The company plans to enroll approximately 8,000 individuals overall.

"This partnership with Geisinger helps ensure communities across Pennsylvania are on the forefront of research," Freenome Chief Medical Officer Lance Baldo said in a statement.

The health system comprises 10 hospital campuses and 130 clinic sites, reaching more than 550,000 patients across Pennsylvania in both urban and rural communities.

"Studies like the Sanderson Study will help us bring innovative care to our patients and, we hope, diminish the burden of cancer in our communities," said Adam Buchanan, principal investigator for the study at Geisinger.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.